Embecta Corp. (EMBC)
(Delayed Data from NSDQ)
$14.25 USD
+0.17 (1.21%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $14.24 -0.01 (-0.07%) 7:58 PM ET
3-Hold of 5 3
A Value F Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$14.25 USD
+0.17 (1.21%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $14.24 -0.01 (-0.07%) 7:58 PM ET
3-Hold of 5 3
A Value F Growth D Momentum D VGM
Zacks News
Embecta Corp. (EMBC) Crossed Above the 200-Day Moving Average: What That Means for Investors
by Zacks Equity Research
Good things could be on the horizon when a stock surpasses the 200-day simple moving average. How should investors react?
Embecta Corp. (EMBC) Recently Broke Out Above the 50-Day Moving Average
by Zacks Equity Research
Good things could be on the horizon when a stock surpasses the 50-Day simple moving average. How should investors react?
Company News for May 15, 2023
by Zacks Equity Research
Companies in The News Are: IAG, SLF, NWSA, EMBC.
Embecta Corp. (EMBC) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Embecta Corp. (EMBC) closed the most recent trading day at $28.52, moving -1.82% from the previous trading session.
Embecta (EMBC) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
Embecta's (EMBC) diabetes care business is expected to have progressed in the fiscal second quarter banking on strong execution of its three strategic pillars.
Embecta Corp. (EMBC) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Embecta Corp. (EMBC) closed at $27.36 in the latest trading session, marking a -1.12% move from the prior day.
Embecta Corp. (EMBC) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Embecta Corp. (EMBC) closed at $29.46, marking a +0.58% move from the previous day.
Here's Why You Should Retain Centene (CNC) in Your Portfolio
by Zacks Equity Research
Strong membership growth, contract wins, accretive acquisitions and streamlining of businesses poise Centene (CNC) well for growth.
Reasons to Retain ShockWave Medical (SWAV) in Your Portfolio
by Zacks Equity Research
ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.
Here's Why You Should Retain McKesson (MCK) Stock for Now
by Zacks Equity Research
McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.
New Strong Buy Stocks for April 4th
by Zacks Equity Research
EMBC, BNPQY, OLLI, CASY and JRVR have been added to the Zacks Rank #1 (Strong Buy) List on April 4, 2023.
Best Momentum Stocks to Buy for March 30th
by Zacks Equity Research
HQI, EMBC and DTC made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on March 30, 2023.
New Strong Buy Stocks for March 30th
by Zacks Equity Research
HQI, EMBC, DTC, GSBD and ARLP have been added to the Zacks Rank #1 (Strong Buy) List on March 30, 2023.
Here's Why You Should Retain Elevance (ELV) in Your Portfolio
by Zacks Equity Research
Strong local presence, improving top line, membership hike and significant new contracts in its government business poise Elevance Health (ELV) well for growth.
3 Medical Services Stocks to Buy Amid Industry Challenges
by Urmimala Biswas
The Zacks Medical - Services industry is growing on digital healthcare adoption. EMBC, INNV and OCX are set to gain the most. However, staffing shortages may disrupt the trend.
Reasons to Retain ShockWave Medical (SWAV) in Your Portfolio
by Zacks Equity Research
ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.
Best Momentum Stocks to Buy for February 24th
by Zacks Equity Research
PLL, TXT and EMBC made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on February 24, 2023.
New Strong Buy Stocks for February 24th
by Zacks Equity Research
PLL, TXT, EMBC, DE and LCNB have been added to the Zacks Rank #1 (Strong Buy) List on February 24, 2023.
Best Value Stocks to Buy for February 24th
by Zacks Equity Research
DTEGY, TXT and EMBC made it to the Zacks Rank #1 (Strong Buy) value stocks list on February 24, 2023.
New Strong Buy Stocks for February 21st
by Zacks Equity Research
EMBC, INSP, REPYY, BZLFY and CVI have been added to the Zacks Rank #1 (Strong Buy) List on February 21, 2023.